Press ReleasesSTMicroelectronics Announces Status of Common Share Repurchase Program By globenewswire June 9, 2025 0 0 STMicroelectronics Announces Status of Common Share Repurchase Program STMicroelectronics Announces Status ofCommon Share Repurchase Program Source: https://www.globenewswire.com/news-release/2025/06/09/3095771/0/en/STMicroelectronics-Announces-Status-of-Common-Share-Repurchase-Program.html Tagscommon sharenewsNL0000226223NYSE:STMParis:STMPArepurchasesharesharessourcestockUS8610121027 Previous articleCarrier Unveils Bold New Brand Identity, Purpose and Tagline, Marking a New Era of Global LeadershipNext articleMaitong Sunshine and Qiannan Yunxiang Industry Join Hands to Create a Benchmark for Cultural Tourism Integration in the New Era globenewswire Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations July 3, 2025 ASIA’S 50 BEST BARS 2025 REVEALS THE ESTABLISHMENTS RANKED ON THE EXTENDED 51-100 LIST July 3, 2025 ASIA’S 50 BEST BARS 2025 REVEALS THE ESTABLISHMENTS RANKED ON THE EXTENDED 51-100 LIST July 3, 2025 Blokees Becomes Exclusive Strategic Partner of “Journey of Light: A Glimpse into Ultraman’s 60th Anniversary” Exhibition July 3, 2025 First AML expands Tranche 2 leadership in Australia following major client wins across law and real estate July 3, 2025 Lake Chelan Health enters into Prime Vendor agreement with Medline July 3, 2025 Recent News Blokees Becomes Exclusive Strategic Partner of “Journey of Light: A Glimpse into Ultraman’s 60th Anniversary” Exhibition ASIA’S 50 BEST BARS 2025 REVEALS THE ESTABLISHMENTS RANKED ON THE EXTENDED 51-100 LIST Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations